The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival
Open accessAbstract
Laboratory models show that the beta-blocker, propranolol, can inhibit norepinephrine-induced breast cancer cell migration. We hypothesised that breast cancer patients receiving beta-blockers for hypertension would show reduced metastasis and improved clinical outcome. Three patient subgroups were identified from the medical records of 466 consecutive female patients (median age 57, range 28-71) with operable breast cancer and follow-up (>10 years). Two subgroups comprised 43 and 49 hypertensive patients treated with beta-blockers or other antihypertensives respectively, prior to cancer diagnosis. 374 patients formed a non-hypertensive control group. Metastasis development, disease free interval, tumour recurrence and hazards risk were statistically compared between groups. Kaplan-Meier plots were used to model survival and DM. Beta-blocker treated patients showed a significant reduction in metastasis development (p=0.026), tumour recurrence (p=0.001), and longer disease free interval (p=0.01). In addition, there was a 57% reduced risk of metastasis (Hazards ratio=0.430; 95% CI=0.200-0.926, p=0.031), and a 71% reduction in breast cancer mortality after 10 years (Hazards ratio=0.291; 95% CI=0.119-0.715, p=0.007). This proof-of-principle study showed beta-blocker therapy significantly reduces distant metastases, cancer recurrence, and cancer-specific mortality in breast cancer patients suggesting a novel role for beta-blocker therapy. A larger epidemiological study leading to randomised clinical trials is needed for breast and other cancer types including colon, prostate and ovary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dhabhar, F. S. (2009) · Neuroimmunomodulation · doi:10.1159/000216188 · Cited by 903
Sporn, M. B. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91015-6 · Cited by 692
Stress hormone-mediated invasion of ovarian cancer cells
Sood, A. K., Bhatty, R., Kamat, A. A., Landen, C. N., Han, L., Thaker, P. H., Li, Y., Gershenson, D. M., Lutgendorf, S., & Cole, S. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1698 · Cited by 491
Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters
Entschladen, F., Drell, T. L., Lang, K., Joseph, J., & Zaenker, K. S. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01431-7 · Cited by 334
Self-citationNorepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers.
Masur, K., Niggemann, B., Zänker, K. S., & Entschladen, F. (2001) · PubMed · Cited by 308
Self-citationPalm, D., Lang, K., Niggemann, B., Drell, T. L., Masur, K., Zaenker, K. S., & Entschladen, F. (2006) · International Journal of Cancer · doi:10.1002/ijc.21723 · Cited by 298
Self-citationDrell, T. L., Joseph, J., Lang, K., Niggemann, B., Zaenker, K. S., & Entschladen, F. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1024491219366 · Cited by 277
Self-citationLang, K., Drell, T. L., Lindecke, A., Niggemann, B., Kaltschmidt, C., Zaenker, K. S., & Entschladen, F. (2004) · International Journal of Cancer · doi:10.1002/ijc.20410 · Cited by 256
Self-citationCancer metastasis as a therapeutic target
Sleeman, J., & Steeg, P. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.039 · Cited by 198
Li, C. I., Malone, K. E., Weiss, N. S., Boudreau, D. M., Cushing‐Haugen, K. L., & Daling, J. R. (2003) · Cancer · doi:10.1002/cncr.11663 · Cited by 130
Prevention of pancreatic cancer by the beta-blocker propranolol
Al-Wadei, H. A. N., Al-Wadei, M. H., & Schuller, H. M. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832bd1e3 · Cited by 121
Zhang, D., Ma, Q., Shen, S., & Hu, H. (2008) · Pancreas · doi:10.1097/mpa.0b013e318184f50c · Cited by 116
Functionalβ-adrenergic receptors in breast cancer cells
Vandewalle, B., Révillion-Carette, F., & Lefèbvre, J. L. (1990) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01612908 · Cited by 92
A 2009 Update on the Treatment of Patients with Hormone Receptor—Positive Breast Cancer
Cleator, S. J., Ahamed, E., Coombes, R. C., & Palmieri, C. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.001 · Cited by 82
β-Blocker Use for the Stages of Heart Failure
Klapholz, M. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.8.718 · Cited by 82
Expression of β2‐adrenergic receptor in oral squamous cell carcinoma
Shang, Z. J., Liu, K., & Liang, D. F. (2009) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2008.00691.x · Cited by 81
Hypertension, Heart Rate, Use of Antihypertensives, and Incident Prostate Cancer
Fitzpatrick, A. L., Daling, J. R., Furberg, C. D., Kronmal, R. A., & Weissfeld, J. L. (2001) · Annals of Epidemiology · doi:10.1016/s1047-2797(01)00246-0 · Cited by 78
Harris, A. M., Warner, B. W., Wilson, J. M., Becker, A., Rowland, R. G., Conner, W. T., Lane, M. T., Kimbler, K. D., Durbin, E. B., Baron, A. T., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.06.043 · Cited by 73
Entschladen, F., Drell, T. L., Lang, K., Joseph, J., & Zaenker, K. S. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053382197 · Cited by 67
Self-citationTargeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review
Rosen, L. S., Ashurst, H. L., & Chap, L. I. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0145 · Cited by 62
Enhancing the Efficacy of Hormonal Agents with Selected Targeted Agents
Johnston, S. R. D. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.s.003 · Cited by 56
Spears, M., & Bartlett, J. (2009) · Expert opinion on therapeutic targets · doi:10.1517/14728220902911509 · Cited by 35
Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke
Weber, R., Weimar, C., & Diener, H. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903048934 · Cited by 14
Inhibitors for Metastasis Development
Lang, K., Drell, T. L., Zaenker, K. S., & Entschladen, F. (2006) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489206775246511 · Cited by 11
Self-citation
Cited by
Mehta, L. S., Watson, K. E., Barac, A., Beckie, T. M., Bittner, V., Cruz-Flores, S., Dent, S., Kondapalli, L., Ky, B., Okwuosa, T., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000556 · Cited by 848
Molecular Pathways: Beta-Adrenergic Signaling in Cancer
Cole, S. W., & Sood, A. K. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0641 · Cited by 681
Sympathetic nervous system regulation of the tumour microenvironment
Cole, S. W., Nagaraja, A. S., Lutgendorf, S. K., Green, P. A., & Sood, A. K. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3978 · Cited by 576
Beta Blockers and Breast Cancer Mortality: A Population- Based Study
Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5422 · Cited by 529
Exploiting the critical perioperative period to improve long-term cancer outcomes
Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487
Metadata
- Authors
- Powe, D. G., Voss, M. J., Zänker, K. S., Habashy, H. O., Green, A. R., Ellis, I. O., & Entschladen, F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2010-10-19
- Volume
- 1
- Issue
- 7
- Pages
- 628-638
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2150740158
- Cited by
- 453
- References
- 24
- FWCI
- 19.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.